# Alnylam Pharmaceuticals, Inc. (ALNY) — Stock CV

Alnylam Pharmaceuticals, Inc. is a $31.1B healthcare company. Revenue grew 95.1% over the last year, and it keeps 17¢ of every dollar of sales as profit. It trades at 38.5× earnings — near the lowest of its own history.

> Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression.

## Identity

- **Ticker**: ALNY
- **Sector**: Healthcare
- **Industry**: Pharmaceutical Preparations
- **Headquarters**: CAMBRIDGE, MA
- **Employees**: 2 500
- **Website**: https://www.alnylam.com
- **Market cap**: $31.1B
- **Last price**: $232.60
- **Financial profile**: Strong

## Vitals (TTM)

- **Revenue**: $4.80B
- **Net income**: $808M
- **Free cash flow**: $794M
- **P/E**: 38.5
- **Revenue growth (YoY)**: 95.1%

## Skills (profile scores, 0–100)

| Pillar | Score |
|---|---|
| Valuation | 47 |
| Growth | 50 |
| Profitability | 65 |
| Health | 60 |
| Quality | 57 |
| Moat | 25 |

## Qualifications (beginner checklist) — 8 of 10 passed

- [x] Revenue growing — +95.1% YoY
- [x] Profitable — $808M TTM
- [x] Profit growing — +212.8% YoY
- [x] Generates cash — $794M TTM
- [x] Debt under control — current ratio 3.05
- [x] Established company — $31.1B market cap
- [ ] Not printing shares — +13.7% shares over ~5y
- [ ] Proven track record — 1/10 profitable years
- [x] Financially stable — Altman Z 4.4 — safe
- [x] Valuation not extreme — P/E 38.5

## Experience (career milestones)

- **FY2025** — Turned profitable: $314M net income after a loss year
- **FY2025** — Best year on record: $314M net income
- **FY2022** — Revenue crossed $1B: $1.04B for the year
- **2016** — The company purchased land in Norton, Massachusetts to build a manufacturing facility
- **2014** — Sanofi Genzyme acquired a 12 percent stake in Alnylam and increased its rights to several of the company's…
- **2003** — The firm merged with the German pharmaceutical company, Ribopharma AG
- **2002** — The company was founded in 2002 and is headquartered in Cambridge, Massachusetts

## Strengths

- High gross margin (79.7%)
- Revenue growing 95.1% year over year
- Strong cash conversion — FCF is 16.5% of revenue
- Altman Z-Score 4.40 — low bankruptcy-risk zone

## Watch-outs

- Loss-making in 9 of the recent years

## Track record

| Year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| FY2021 | $844M | -$853M | -$718M |
| FY2022 | $1.04B | -$1.13B | -$613M |
| FY2023 | $1.83B | -$440M | $41.9M |
| FY2024 | $2.25B | -$278M | -$42.6M |
| FY2025 | $3.71B | $314M | $465M |

---

Source: https://stockcv.com/ALNY — derived from company filings; may be delayed or incomplete. Information, not investment advice.